Cargando…

Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen

Detalles Bibliográficos
Autores principales:	Pareek, Anil, Bhandari, Sudhir, Mehta, Ravi Tejraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853251/ https://www.ncbi.nlm.nih.gov/pubmed/32811798 http://dx.doi.org/10.4103/ijmr.IJMR_3077_20

Ejemplares similares

Hydroxychloroquine and QT prolongation: reassuring data in approved indications
por: Pareek, Anil, et al.
Publicado: (2020)

Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
por: Principi, Nicola, et al.
Publicado: (2020)

Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Pareek, Anil, et al.
Publicado: (2019)

Hydroxychloroquine prophylaxis for COVID-19 contacts in India
por: Rathi, Sahaj, et al.
Publicado: (2020)

Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics()
por: Pareek, Anil, et al.
Publicado: (2020)

Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach
por: Tilangi, Praveen, et al.
Publicado: (2020)

Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?
por: Kaur, Hardeep, et al.
Publicado: (2021)

Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
por: Mehta, Sudhir, et al.
Publicado: (2020)

Side effects of hydroxychloroquine prophylaxis against COVID-19 in healthcare workers
por: Dixit, Prashant Kumar, et al.
Publicado: (2021)

Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection
por: Yadav, Reetika Malik, et al.
Publicado: (2021)

Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers
por: Karim, Habib M.R., et al.
Publicado: (2020)

Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
por: Mehta, Ravi Tejraj, et al.
Publicado: (2018)

Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence
por: Mehta, Ravi Tejraj, et al.
Publicado: (2019)

Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?
por: Shankar, Pathiyil Ravi, et al.
Publicado: (2021)

Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed()
por: Tahiri Joutei Hassani, Rachid, et al.
Publicado: (2020)

REVEAL Study: Reveals the Limitations of Cholesteryl Ester Transfer Protein Inhibition
por: Pareek, Anil, et al.
Publicado: (2018)

Hydroxychloroquine and COVID-19: a tale of populism and obscurantism
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2021)

Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2
por: Neves, Fabricio Souza
Publicado: (2020)

Risks of hydroxychloroquine use for COVID-19 prophylaxis
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Hydroxychloroquine as Prophylaxis for COVID-19: A Review
por: Monti, Manuela, et al.
Publicado: (2020)

Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
por: Alizargar, Javad
Publicado: (2020)

Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
por: Afra, TP, et al.
Publicado: (2020)

Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception?
por: Manjunath, B.G., et al.
Publicado: (2020)

The Swedish COVID-19 strategy revisited
por: Claeson, Mariam, et al.
Publicado: (2021)

Need to revisit vitamin A supplementation programme in India
por: Raman, J.K., et al.
Publicado: (2014)

Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Response to: “Risks of hydroxychloroquine use for COVID-19 prophylaxis”
por: Grant-Kels, Jane M.
Publicado: (2020)

Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
por: Carafoli, Ernesto
Publicado: (2021)

Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis
por: Faruqui, Atiya R., et al.
Publicado: (2021)

COVID-19: Hydroxychloroquine prophylaxis is just a prophylaxis! Be careful and perceive it right
por: Garg, Rakesh, et al.
Publicado: (2022)

Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients?
por: Ayerbe, Luis, et al.
Publicado: (2021)

Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
por: Bonny, Aimé, et al.
Publicado: (2020)

Mefloquine as a prophylaxis for malaria needs to be revisited
por: Ahmad, Sundus Shafat, et al.
Publicado: (2021)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Revisiting undergraduate practical pharmacology
por: Naeem, Syed Shariq, et al.
Publicado: (2012)

Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians
por: Schreiber, Karen, et al.
Publicado: (2020)

Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
por: Honoré, Stéphane, et al.
Publicado: (2021)

Hydroxychloroquine for early treatment of COVID-19: Absence of evidence is different from evidence of absence
por: Furlan, Leonardo
Publicado: (2022)

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
por: Boulware, David R., et al.
Publicado: (2020)

Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers
por: Simova, I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gacki5u3ekmsh9c4mpa67dqpl2